The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

### 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

- It was raised by consultees that children should have access to this drug and that this could potentially be an equality issue.
- It was raised by consultees that certain ethnic minorities might benefit more from therapy with belimumab than others, as the prevalence of SLE is greater in certain populations.
- It was also raised if compliance with the therapy could potentially be an equality issue, as patients would need hospital admission to receive this drug.

### 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

- The manufacturer confirmed at the scoping workshop that a marketing authorisation will not be sought for children and therefore an appraisal should focus on adult patients with SLE only.
- It was discussed during the scoping workshop that currently there are no data available regarding possible differential outcomes in certain ethnic groups. This was reiterated by the manufacturer who confirmed that the clinical trial evidence does not provide this data. As such the proposed differential benefits of treatment by certain ethnic groups was not thought to
be an issue that would need to be addressed by the Committee.

Equality of access, when concerning the need for hospital admission was not thought to be an equalities issue.

It is envisaged that none of these issues represent equalities issues that would need to be addressed by the Committee.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

It was agreed that no changes were necessary.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

N/A

Approved by Associate Director (name): Frances Sutcliffe

Date: 15/02/2011